# Compass Therapeutics, Inc.: financial statements, quarterly

CMPX · Nasdaq · CIK 1738021 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cmpx.md) · [Financials](/companies/cmpx/financials.md) · [Filings](/companies/cmpx/filings.md) · [Insiders](/companies/cmpx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cmpx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001171843-24-006248.md) | [0.0 d](/filings/0001171843-25-001106.md) | not reported | [0.9](/filings/0001171843-25-005261.md) | [0.0](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | not reported | [0.0](/filings/0001171843-25-005261.md) | [0.0](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | not reported | not reported |
| Research and development | $m | not reported | not reported | [9.5](/filings/0001171843-25-002953.md) | [11.2](/filings/0001171843-25-005261.md) | [8.6](/filings/0001171843-25-007005.md) | [13.0 d](/filings/0001171843-26-001337.md) | [13.1](/filings/0001171843-26-003006.md) | [16.4](/filings/0001171843-25-005261.md) | [12.8](/filings/0001171843-25-007005.md) | [13.7 d](/filings/0001171843-26-001337.md) | [13.4](/filings/0001171843-26-003006.md) | not reported |
| Operating income | $m | [(11.9)](/filings/0001171843-24-006248.md) | [(15.4) d](/filings/0001171843-25-001106.md) | [(12.8)](/filings/0001171843-25-002953.md) | [(15.0)](/filings/0001171843-25-005261.md) | [(12.2)](/filings/0001171843-25-007005.md) | [(16.6) d](/filings/0001171843-26-001337.md) | [(18.0)](/filings/0001171843-26-003006.md) | [(21.1)](/filings/0001171843-26-005295.md) | [(15.8)](/filings/0001171843-25-007005.md) | [(18.0) d](/filings/0001171843-26-001337.md) | [(20.3)](/filings/0001171843-26-003006.md) | [(27.0)](/filings/0001171843-26-005295.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001171843-23-006912.md) | [0.0 d](/filings/0001171843-25-001106.md) | [0.0](/filings/0001171843-25-002953.md) | [0.0](/filings/0001171843-24-004670.md) | not reported | not reported | [0.0](/filings/0001171843-25-002953.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(10.0)](/filings/0001171843-24-006248.md) | [(13.4) d](/filings/0001171843-25-001106.md) | [(10.8)](/filings/0001171843-25-007005.md) | [(13.1)](/filings/0001171843-25-007005.md) | [(10.5)](/filings/0001171843-25-007005.md) | [(15.0) d](/filings/0001171843-26-001337.md) | [(16.6)](/filings/0001171843-26-005295.md) | [(19.9)](/filings/0001171843-26-005295.md) | [(14.3)](/filings/0001171843-25-007005.md) | [(15.7) d](/filings/0001171843-26-001337.md) | [(18.3)](/filings/0001171843-26-005295.md) | [(25.2)](/filings/0001171843-26-005295.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.08)](/filings/0001171843-24-006248.md) | not reported | [(0.08)](/filings/0001171843-25-002953.md) | [(0.10)](/filings/0001171843-25-005261.md) | [(0.08)](/filings/0001171843-25-007005.md) | not reported | [(0.12)](/filings/0001171843-26-003006.md) | [(0.14)](/filings/0001171843-26-005295.md) | [(0.08)](/filings/0001171843-25-007005.md) | not reported | [(0.10)](/filings/0001171843-26-003006.md) | [(0.13)](/filings/0001171843-26-005295.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [30.4](/filings/0001171843-23-006912.md) | [24.2](/filings/0001171843-25-001106.md) | [43.5](/filings/0001171843-25-002953.md) | [19.4](/filings/0001171843-25-005261.md) | [19.4](/filings/0001171843-25-007005.md) | [43.5](/filings/0001171843-26-001337.md) | [41.0](/filings/0001171843-26-003006.md) | [22.9](/filings/0001171843-26-005295.md) | [46.2](/filings/0001171843-25-007005.md) | [30.6](/filings/0001171843-26-005295.md) | [55.2](/filings/0001171843-26-003006.md) | [35.5](/filings/0001171843-26-005295.md) |
| Current assets | $m | [167](/filings/0001171843-23-006912.md) | [154](/filings/0001171843-25-001106.md) | [159](/filings/0001171843-24-002785.md) | [154](/filings/0001171843-24-004670.md) | [141](/filings/0001171843-24-006248.md) | [133](/filings/0001171843-26-001337.md) | [124](/filings/0001171843-25-002953.md) | [106](/filings/0001171843-25-005261.md) | [221](/filings/0001171843-25-007005.md) | [210](/filings/0001171843-26-005295.md) | [196](/filings/0001171843-26-003006.md) | [181](/filings/0001171843-26-005295.md) |
| Total assets | $m | [170](/filings/0001171843-23-006912.md) | [157](/filings/0001171843-25-001106.md) | [161](/filings/0001171843-24-002785.md) | [156](/filings/0001171843-24-004670.md) | [149](/filings/0001171843-24-006248.md) | [140](/filings/0001171843-26-001337.md) | [131](/filings/0001171843-25-002953.md) | [117](/filings/0001171843-25-005261.md) | [231](/filings/0001171843-25-007005.md) | [220](/filings/0001171843-26-005295.md) | [205](/filings/0001171843-26-003006.md) | [190](/filings/0001171843-26-005295.md) |
| Current liabilities | $m | [9.1](/filings/0001171843-23-006912.md) | [7.8](/filings/0001171843-25-001106.md) | [3.9](/filings/0001171843-24-002785.md) | [9.5](/filings/0001171843-24-004670.md) | [4.4](/filings/0001171843-24-006248.md) | [8.9](/filings/0001171843-26-001337.md) | [14.9](/filings/0001171843-25-002953.md) | [13.9](/filings/0001171843-25-005261.md) | [12.4](/filings/0001171843-25-007005.md) | [14.0](/filings/0001171843-26-005295.md) | [10.3](/filings/0001171843-26-003006.md) | [16.1](/filings/0001171843-26-005295.md) |
| Total liabilities | $m | [10.0](/filings/0001171843-23-006912.md) | [8.3](/filings/0001171843-25-001106.md) | [4.1](/filings/0001171843-24-002785.md) | [9.5](/filings/0001171843-24-004670.md) | [10.8](/filings/0001171843-24-006248.md) | [15.2](/filings/0001171843-26-001337.md) | [21.2](/filings/0001171843-25-002953.md) | [23.5](/filings/0001171843-25-005261.md) | [21.6](/filings/0001171843-25-007005.md) | [22.8](/filings/0001171843-26-005295.md) | [18.7](/filings/0001171843-26-003006.md) | [24.1](/filings/0001171843-26-005295.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [160](/filings/0001171843-24-006248.md) | [149](/filings/0001171843-26-001337.md) | [157](/filings/0001171843-25-007005.md) | [146](/filings/0001171843-25-007005.md) | [138](/filings/0001171843-25-007005.md) | [125](/filings/0001171843-26-005295.md) | [110](/filings/0001171843-26-005295.md) | [93.2](/filings/0001171843-26-005295.md) | [210](/filings/0001171843-25-007005.md) | [197](/filings/0001171843-26-005295.md) | [186](/filings/0001171843-26-005295.md) | [166](/filings/0001171843-26-005295.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.9) d](/filings/0001171843-24-006248.md) | [(12.4) d](/filings/0001171843-25-001106.md) | [(13.9)](/filings/0001171843-25-002953.md) | [(10.8) d](/filings/0001171843-25-005261.md) | [(11.1) d](/filings/0001171843-25-007005.md) | [(9.2) d](/filings/0001171843-26-001337.md) | [(13.2)](/filings/0001171843-26-003006.md) | [(11.8) d](/filings/0001171843-26-005295.md) | [(10.8) d](/filings/0001171843-25-007005.md) | [(13.3) d](/filings/0001171843-26-001337.md) | [(17.3)](/filings/0001171843-26-003006.md) | [(14.7) d](/filings/0001171843-26-005295.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001171843-24-006248.md) | [0.0 d](/filings/0001171843-25-001106.md) | [0.0](/filings/0001171843-25-002953.md) | [0.0 d](/filings/0001171843-25-005261.md) | [0.0 d](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | [0.0](/filings/0001171843-26-003006.md) | [0.0 d](/filings/0001171843-26-005295.md) | [0.0 d](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | [0.1](/filings/0001171843-26-003006.md) | [0.2 d](/filings/0001171843-26-005295.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [138](/filings/0001171843-25-007005.md) | [138](/filings/0001171843-26-003006.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 180,087,915 at 2026-07-28, from the cover of the [10-Q filed 2026-08-06](/filings/0001171843-26-005295.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.